×

Zealand informs of new data on iGlarLixi and proprietary preclinical peptide drug candidates to be presented at the 76th Annual American Diabetes Associations Scientific Sessions

  • First time presentations at a scientific congress of results from the two pivotal Phase III trials, LixiLan-L and LixiLan-O, with iGlarLixi
  • Presentations in two oral sessions on Sunday, 12 June 2016

COPENHAGEN, Denmark, June 8, 2016 (GLOBE NEWSWIRE) -- Zealand informs that new Phase III data will be presented on iGlarLixi, the fixed-ratio titratable combination of insulin glargine 100 Units/mL (Lantus(r)) and lixisenatide, at the upcoming 76th Scientific Sessions of the American Diabetes Association (ADA), taking place 10- 14 June 2016 in New Orleans, the United States. This is the first time results from these pivotal trials are being presented at a scientific congress.

Further at ADA, Zealand will present new data from its proprietary preclinical activities, including on a novel peptide drug candidate from its preclinical pipeline.

Abstracts of the ADA presentations are available at: http://app.core-apps.com/tristar_ada16

IGlarLixi - Oral presentations of results from two pivotal Phase III trials, LixiLan-O and LixiLan-L

Presentation of results from LixiLan-O (# 186-OR):

"Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial"

When: Sunday, 12 June 2016 at 8.45 am CDT

Presenter: Julio Rosenstock, MD, Dallas Diabetes and Endocrine Center

Location: La Nouvelle Orleans AB

Link to abstract: http://app.core-apps.com/tristar_ada16/event/2dcea2d3f4cca64c82bb162014ab0feb

Presentation of results from LixiLan-L (# 238-OR):

"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Patients with T2DM: The LixiLan-L Trial"

When: Sunday, 12 June 2016 at 2.30 pm CDT

Presenter: Vanita R. Aroda, MD, Medstar Health Research Institute

Location: La Nouvelle Orleans AB

Link to abstract: http://app.core-apps.com/tristar_ada16/event/9b73fdfd4b7befbd3fa1b130a88c5086

Zealand poster presentations

Zealand scientists will present posters with new data from two of the company's proprietary preclinical peptide drug projects:

"Antidiabetic Effects of Novel, Long-Acting Amylin Analogue ZP4982 in ZDF Rats" (# 283-LB)

When: 12 June 2016 at 12 pm CDT

Presenter: Jolanta Skarbaliene, Zealand, Denmark

Location: Poster Hall (D-E)

Link to abstract: http://app.core-apps.com/tristar_ada16/abstract/e44e3c20f4b9cf62bd1796c12c19074b

" Model of the Glucose-Insulin-Glucagon Dynamics after Subcutaneous Administration of a Glucagon Rescue Bolus in Healthy Humans" (# 1759-P)

When: 12 June 2016 at 12 pm CDT

Presenter: Sabrina L. Wendt, Zealand, Denmark

Location: Poster Hall (D-E)

Link to abstract: http://app.coreapps.com/tristar_ada16/abstract/92b0eac0f984437a5bebc08c57a7b135

Source: Zealand Pharma A/S